米力农联合艾司洛尔治疗危重型手足口病的效果观察

Milrinone combined with esmolol in treatment of critically severe hand-foot-and-mouth disease

目的探讨分析米力农联合艾司洛尔在危重型手足口病治疗中的临床应用价值。方法2013年6月至2015年4月收住本院的危重型手足口病患儿82例，依据随机数字表法将其分为研究组（n=40）和对照组（n=42）。在常规处理基础上，对照组米力农治疗，而研究组米力农联合艾司洛尔治疗。治疗前与治疗24h后测量患儿血压、心率、左室射血分数以及心排出量，取静脉血测定血清脑钠肽和去甲肾上腺素水平。结果治疗前，两组各指标差异无统计学意义（P〉0．05）。治疗后，两组血压、心率、心功能以及实验室指标均优于治疗前（P〈0．05），但研究组改善程度优于对照组（P〈0．05）。结论米力农联合艾司洛尔治疗危重型手足口病可在较短时间内改善患儿心功能，提高临床治疗效果。

Objective To observe the effect of milrinone combined with esmolol in the treatment of severe hand-foot-and-mouth disease（HFMD）. Methods 82 children with critically severe HFMD were enrolled and were randomly divided into a control group（n=42） and a study group（n=40）. The control group were treated with milrinone and the observation group milrinone and esmolol. The blood pressure, heart rate, cardiac output, left ventrieular ejection fraction, norepinephrine, and brain natriuretic peptide were detected before and 24 h after the treatment. Results There were no statistical differences in all the indicators between these 2 groups before the treatment （P〉0.05）. The blood pressure, heart rate, cardiac function, and laboratory indexes were better after than before the treatment in both groups （P〈0.05） and were better in the study group than in the control group after the treatment （P〈0.05）. Conclusions Milrinone combined with esmolol in the treatment of critically severe HFMD can improve the children＇s cardiac function in a short time and clinical treatment effect.